G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma. [electronic resource]
Producer: 20040623Description: 1078-84 p. digitalISSN:- 0887-6924
- Adult
- Aged
- Anemia -- etiology
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- B-Lymphocytes
- Blood Platelets
- Dexamethasone -- therapeutic use
- Doxorubicin -- therapeutic use
- Drug Resistance, Neoplasm
- Female
- Genetic Therapy -- adverse effects
- Humans
- Male
- Middle Aged
- Monocytes
- Multiple Myeloma -- drug therapy
- Oligonucleotides, Antisense -- administration & dosage
- Proto-Oncogene Proteins c-bcl-2 -- genetics
- T-Lymphocytes
- Vincristine -- therapeutic use
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.